On the latter point, it is important to keep in mind that these results are limited to the specific timeframe we studied and to the specific experimental conditions of this study (i.e., acute cannabis administration in cannabis users)
That's a different approach for the agency, which typically drafts its letters in highly bureaucratic language citing specific FDA regulations
This is especially important if you have been managing conditions without formal medical follow-up
Introducing an unknown variable in the form of an impurity can invalidate months or even years of work
Results Dual blockade of GDF8 and ActA during GLP-1 RA-induced weight loss in obese mice preserves lean mass while also increasing fat loss To test whether dual blockade of GDF8 and ActA could help attenuate loss of lean mass during GLP-1 RA-induced weight loss, we tested our antibody combination in diet-induced obese (DIO) mice during treatment with the GLP-1 RA semaglutide (approved by the US Food and Drug Administration as a therapeutic for obesity and diabetes with the brand names of Ozempic and Wegovy)
We conducted a prospectively designed, retrospectively analyzed cohort study at the Seoul National University Bundang Hospitals Endocrinology and Metabolism Clinic (IRB B-2401-879-106)
